Announcement of application for approval in Japan of DPT-IPV vaccine
Posted: 20 February 2013 | | No comments yet
DPT-IPV vaccine for prevention of Diphtheria, Pertussis, Tetanus, and acute Poliomyelitis…
Daiichi Sankyo Co., Ltd.(Head office: Chuo-ku, Tokyo; President and Representative Director: Joji Nakayama; hereafter, Daiichi Sankyo) and Sanofi Pateur KK (Head office: Shinjuku-ku, Tokyo; President: Thomas Triomphe) today announced that Kitasato Daiichi Sankyo K.K. (Head office: Kitamoto city, Saitama; President: Masahiro Okabe), a member of the Daiichi Sankyo Group, has applied for approval of “tetravalent combination vaccine (DPT-IPV)” in Japan for the prevention of Diphtheria, Pertussis (whooping cough), Tetanus, and acute Poliomyelitis (polio).
The DPT-IPV vaccine, which is supplied in pre-filled syringes, combines DPT vaccine from Kitasato Daiichi Sankyo and the enhanced inactivated Salk Poliomyelitis vaccine (eIPV), from Sanofi Pasteur.
The Daiichi Sankyo Group and Sanofi Pasteur contribute to the protection and improvement of people’s health and hygiene and the enhancement and dissemination of preventive medicine in Japan by supplying vaccines that meet unmet medical needs.
